Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 16 Dec 2019 Status changed from active, no longer recruiting to completed.
- 04 Nov 2019 Planned End Date changed from 17 Dec 2019 to 30 Nov 2020.
- 24 Oct 2018 Planned End Date changed from 30 Nov 2018 to 17 Dec 2019.